<div id="readability-page-1"><p>Pediatrix Medical Group, Inc. (NYSE:MD - Get Free Report) Director Laura Linynsky sold 10,000 shares of the business's stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $21.65, for a total value of $216,500.00. Following the sale, the director owned 32,232 shares in the company, valued at approximately $697,822.80. The trade was a 23.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.</p><h2>Pediatrix Medical Group Trading Up 3.0%</h2><ul><li>MarketBeat Week in Review – 08/18 - 08/22</li></ul><p>Shares of MD traded up $0.66 during midday trading on Monday, hitting $22.59. The stock had a trading volume of 1,259,182 shares, compared to its average volume of 777,751. The business has a 50-day simple moving average of $17.29 and a two-hundred day simple moving average of $15.16. The firm has a market cap of $1.94 billion, a P/E ratio of 17.51 and a beta of 1.20. The company has a current ratio of 1.80, a quick ratio of 1.80 and a debt-to-equity ratio of 0.70. Pediatrix Medical Group, Inc. has a fifty-two week low of $11.84 and a fifty-two week high of $22.60. </p><p>Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.46 by $0.21. Pediatrix Medical Group had a net margin of 5.66% and a return on equity of 18.94%. The business had revenue of $492.88 million during the quarter, compared to the consensus estimate of $476.45 million. During the same quarter in the prior year, the firm earned $0.44 EPS. The firm's quarterly revenue was down 3.6% on a year-over-year basis.  As a group, equities analysts forecast that  Pediatrix Medical Group, Inc. will post 1.38 EPS for the current year. </p><h2>Analyst Ratings Changes</h2><ul><li>Medtronic: The Opportunity Gets Healthier for Income Investors</li></ul><p>A number of brokerages have recently weighed in on MD. Leerink Partners lifted their price target on Pediatrix Medical Group from $14.50 to $17.00 and gave the company a &#34;market perform&#34; rating in a report on Friday, September 5th. Weiss Ratings  restated a &#34;hold (c)&#34; rating on shares of Pediatrix Medical Group in a research report on Wednesday, October 8th. Truist Financial lifted their target price on Pediatrix Medical Group from $17.00 to $24.00 and gave the company a &#34;hold&#34; rating in a research note on Monday. UBS Group increased their price target on shares of Pediatrix Medical Group from $16.50 to $23.00 and gave the stock a &#34;neutral&#34; rating in a research report on Wednesday, November 5th. Finally, Wall Street Zen upgraded shares of Pediatrix Medical Group from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, October 4th. One analyst  has rated the stock with a Buy rating and six have issued  a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Hold&#34; and an average target price of $19.80.</p><p><b>View Our Latest Analysis on MD</b></p><h2>Institutional Investors Weigh In On Pediatrix Medical Group</h2><ul><li>5 Robotics Stocks to Buy for the Future of Automation</li></ul><p>Several large investors have recently made changes to their positions in MD. Marshall &amp; Sullivan Inc. WA bought a new position in  Pediatrix Medical Group during the second quarter valued at approximately $41,000.  Canada Pension Plan Investment Board acquired a new position in shares of  Pediatrix Medical Group during the 2nd quarter worth $83,000.  AlphaQuest LLC raised its holdings in shares of  Pediatrix Medical Group by 16.0% during the 1st quarter. AlphaQuest LLC now owns 5,877 shares of the company's stock valued at $85,000 after purchasing an additional 811 shares in the last quarter.  Quantbot Technologies LP acquired a new stake in shares of  Pediatrix Medical Group in the 2nd quarter valued at $99,000.  Finally, Smartleaf Asset Management LLC lifted its stake in shares of  Pediatrix Medical Group by 10.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 6,250 shares of the company's stock valued at $101,000 after purchasing an additional 601 shares during the last quarter. Institutional investors own  97.71% of the company's stock. </p><h2>Pediatrix Medical Group Company Profile</h2> (Get Free Report)<p>Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Pediatrix Medical Group</li><li>Health Care Stocks Explained: Why You Might Want to Invest</li><li>Shares Down, Price Targets Up: 3 Stocks Upgraded After +10% Drops</li><li>Dividend Capture Strategy: What You Need to Know</li><li>Nuclear Stocks Are Melting Down—Should Investors Panic?</li><li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li><li>Monday.com Opens Generational Opportunity With Manic Sell-Off</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Pediatrix Medical Group Right Now?</h2><p>Before you consider Pediatrix Medical Group, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pediatrix Medical Group wasn't on the list.</p><p>While Pediatrix Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Pediatrix Medical Group Director Laura Linynsky sold 10,000 shares at an average price of $21.65, totaling $216,500, representing a 23.68% decrease in her position. Post-sale, she holds 32,232 shares valued at approximately $697,822.80. The transaction was disclosed to the SEC. The stock recently traded up 3.0% to $22.59, with a market cap of $1.94 billion and a P/E ratio of 17.51. Analysts have mixed ratings, with an average target price of $19.80 and a consensus rating of "Hold."</p>

Pediatrix Medical Group (NYSE:MD) Director Laura Linynsky Sells 10,000 Shares